RecruitingNCT05275075

Identify microRNAs in Cachexia in Pancreatic Carcinoma

Pilot Trial to Identify microRNAs in Cachexia in Patients With Pancreatic Carcinoma


Sponsor

University of Oklahoma

Enrollment

100 participants

Start Date

Dec 7, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects blood samples from patients with operable pancreatic cancer to identify microRNAs — tiny molecules in the blood — that may serve as markers of cancer-related weight loss and muscle wasting (cachexia). **You may be eligible if...** - You are 18 or older with a confirmed or suspected pancreatic tumor diagnosed within the last 12 months - Your cancer is stage I or higher and you are a candidate for surgical removal - You may or may not have received neoadjuvant (pre-surgery) chemotherapy **You may NOT be eligible if...** - Your pancreatic cancer is not surgically removable - You have a cancer diagnosis other than primary pancreatic adenocarcinoma - You are unable or unwilling to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPancreatic cancer microRNA and messenger RNA expression.

Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.


Locations(1)

Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05275075


Related Trials